Research programme: tumour growth factor inhibitors - ApoxisAlternative Names: APRIL inhibitors
Latest Information Update: 23 Nov 2006
At a glance
- Originator Apoxis
- Developer Biogen Idec
- Mechanism of Action Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Nov 2003 IDEC Pharmaceuticals has merged with Biogen to form Biogen Idec
- 02 Jul 2003 Preclinical trials in Cancer in Switzerland (unspecified route)